Global Community

Our community narratives are driven by numbers and valuation.

Author Program NEW

Community Investing Ideas

Global Weekly Picks

PYPL logo
PayPal Holdings

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

PayPal is treated like a business in decline, but the case here is that it only needs to stop slipping for sentiment to improve—and its heavy share buybacks could amplify that recovery if the core stays steady. The bigger question is whether PayPal’s cross‑platform person‑to‑person payments and new AI-driven ways to pay become tailwinds, or whether rising competition and shrinking profit per transaction keep the slide going.
View narrative
US$65
FV
13.0% undervalued intrinsic discount
exit-earnings model with explicit share-count reduction (the standard revenue/margin/PE approach understates PayPal because it ignores the buyback, which is central to this thesis) 1. Revenue FY2030: ~$37.5B (from ~$32B today, ~3.5% CAGR – stabilization only, no reacceleration) 2. Net margin: 15.5% → net income ~$5.8B (cost program partially offsets mix shift) 3. Share count FY2030: ~700M (from ~890M today) Assumes ~5.5% net annual share reduction – deliberately BELOW the current ~9%/yr run-rate. Feasibility check: retiring ~190M shares over 4.5 years costs roughly $3B/yr even at rising prices, well within ~$6.8B annual free cash flow. 4. EPS FY2030: $5.8B / 700M ≈ $8.30 5. Exit multiple: 12x earnings → ~$100 per share in FY2030 (low end of a normal profitable-financial multiple; no premium, zero value assigned to agentic commerce optionality) 6. Discount back 4.5 years at 10% p.a. → fair value today ≈ $65 Every input is conservative on purpose. Kill-switch: if Branded Checkout growth turns negative again, the network is eroding and the thesis is void regardless of this math. Sensitivity: at a 16x exit multiple and the current ~9%/yr buyback pace, the same framework yields ~$85–90. I deliberately anchor on the conservative case.
5.9k
users have viewed this narrative
9users have liked this narrative
2users have commented on this narrative
60users have followed this narrative
CELH logo
Celsius Holdings

From $5M to $2B: Why the 2024 Crash Was the Best Buying Opportunity in Consumer Stocks

A 17-Year Story That Most Investors Only Discovered in the Last Three In 2010, Celsius Holdings (CELH) was generating roughly US$5 million in annual revenue, a forgotten energy drink with niche distribution in Scandinavian gyms and a handful of US health food stores. By the end of 2025, the company had crossed US$2 billion in trailing twelve-month revenue and acquired two major energy drink brands.
View narrative
US$55.43
FV
47.7% undervalued intrinsic discount
20.00%
Revenue growth p.a.
2.4k
users have viewed this narrative
8users have liked this narrative
1users have commented on this narrative
20users have followed this narrative
Load previous narratives
3436 logo
Sumco

Dividend Decisions And Financial Forecasts Will Shape Industry Positioning Ahead

Key Takeaways Strategic focus on leading-edge wafers and technological advancements like 3D structures is set to boost revenue and enhance profitability. Reallocating resources and improving efficiency could optimize operations and stabilize earnings through better inventory management and increased customer demand.Read more

View narrative
JP¥1.72k
127.3% overvalued intrinsic discount
Fair Value
Profit Margin
8.44%
Future PE
20.38x
Price in 2029
JP¥2.35k
CLRB logo
Cellectar Biosciences

Regulatory And Funding Risks Will Test Radiopharmaceutical Pipeline Yet Long Term Prospects Will Improve

Catalysts About Cellectar Biosciences Cellectar Biosciences is a radiopharmaceutical company focused on phospholipid drug conjugates for difficult to treat cancers. What are the underlying business or industry changes driving this perspective?Read more

View narrative
US$10
74.9% undervalued intrinsic discount
Fair Value
Profit Margin
12.51%
Future PE
24.92x
Price in 2029
US$0
ATLC logo
Atlanticus Holdings

Mercury Integration And Repricing Will Transform Scale And Earnings Power Over The Next Cycle

Catalysts About Atlanticus Holdings Atlanticus Holdings provides general purpose and private label credit products to near prime and subprime consumers through cards and point of sale financing partnerships. What are the underlying business or industry changes driving this perspective?Read more

View narrative
US$105
4.1% undervalued intrinsic discount
Fair Value
Revenue
100.59% p.a.
Profit Margin
8.4%
Future PE
5.64x
Price in 2029
US$148.83
ACE logo
Ascelia Pharma

Severe Regulatory And Funding Risks Around Cancer Imaging Will Eventually Reward Patient Safety Focus

Catalysts About Ascelia Pharma Ascelia Pharma develops and commercializes specialty drugs for rare cancer related conditions, focused on diagnostic imaging and oral oncology treatments. What are the underlying business or industry changes driving this perspective?Read more

View narrative
SEK 3.95
87.6% undervalued intrinsic discount
Fair Value
Profit Margin
56.62%
Future PE
16.78x
Price in 2029
SEK 0
OXM logo
Oxford Industries

Upgrading Tommy Bahama And Lilly Pulitzer Platforms Will Improve Efficiency

Key Takeaways Strengthening of omnichannel platforms and engagement in core markets is expected to drive revenue growth, especially for Tommy Bahama. Infrastructure investments and strategic focus on Lilly Pulitzer aim to enhance operational efficiency and net margins through increased full-price sales.Read more

View narrative
US$36.5
10.8% overvalued intrinsic discount
Fair Value
Profit Margin
6.86%
Future PE
6.84x
Price in 2029
US$49.14
CXM logo
Sprinklr

Digital Transformation And AI Will Expand Omni-Channel Markets Amid Uncertainty

Key Takeaways Sprinklr's enterprise-focused strategy, AI-native offerings, and leadership are driving improved renewal cycles, higher margins, and durable long-term revenue growth. Strong digital transformation tailwinds and industry shifts toward SaaS and compliance position Sprinklr to capture expanding market share and accelerate free cash flow.Read more

View narrative
US$12
51.4% undervalued intrinsic discount
Fair Value
Revenue
6.11% p.a.
Profit Margin
8.14%
Future PE
39.8x
Price in 2029
US$15.31